HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

This is a single-arm feasibility trial in which patients with histologically confirmed plasmablastic lymphoma (PBL) with or without HIV, who have achieved a Complete Response or Partial Response after definitive frontline chemotherapy, will receive Elranatamab (Elra) consolidation.

NCT Number	NCT07647432
Lead Sponsor	University of Illinois at Chicago Collaborators: Pfizer
Conditions	Plasmablastic Lymphoma, Hiv, Consolidation
Enrollment	17 participants
Start Date	2026-12-01
Primary Completion	2029-12-01 (estimated)
Study Completion	2030-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-15